Related Experiment Video
Updated: Dec 29, 2025
Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
Published on: August 10, 2017
HDAC6-an Emerging Target Against Chronic Myeloid Leukemia?
Hélène Losson1, Michael Schnekenburger1, Mario Dicato1
1Laboratoire de Biologie Moléculaire et Cellulaire du Cancer, Hôpital Kirchberg 9, rue Edward Steichen, L2540 Luxembourg, Luxembourg.
Abstract:
Imatinib became the standard treatment for chronic myeloid leukemia (CML) about 20 years ago, which was a major breakthrough in stabilizing the pathology and improving the quality of life of patients. However, the emergence of resistance to imatinib and other tyrosine kinase inhibitors leads researchers to characterize new therapeutic targets. Several studies have highlighted the role of histone deacetylase 6 (HDAC6) in various pathologies, including cancer. This protein effectively intervenes in cellular activities by its primarily cytoplasmic localization. In this review, we will discuss the molecular characteristics of the HDAC6 protein, as well as its overexpression in CML leukemic stem cells, which make it a promising therapeutic target for the treatment of CML.
Insights
Histone deacetylase 6 (HDAC6) is overexpressed in chronic myeloid leukemia (CML) stem cells. Targeting HDAC6 presents a promising new therapeutic strategy for CML treatment, addressing imatinib resistance.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Imatinib revolutionized chronic myeloid leukemia (CML) treatment, establishing a standard of care for two decades.
- Emerging resistance to imatinib and other tyrosine kinase inhibitors necessitates the identification of novel therapeutic targets in CML.
Purpose of the Study:
- To review the molecular characteristics of histone deacetylase 6 (HDAC6).
- To discuss the overexpression of HDAC6 in CML leukemic stem cells.
- To evaluate HDAC6 as a potential therapeutic target for CML.
Main Methods:
- Literature review of studies on HDAC6.
- Analysis of HDAC6's role in cellular activities and its cytoplasmic localization.
- Examination of HDAC6 expression patterns in CML.
Main Results:
- HDAC6 plays a significant role in various cellular functions due to its cytoplasmic localization.
- Overexpression of HDAC6 has been observed in CML leukemic stem cells.
Conclusions:
- HDAC6's molecular properties and its overexpression in CML stem cells position it as a promising therapeutic target.
- Targeting HDAC6 may offer a new strategy to overcome imatinib resistance in CML patients.
